Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2019 1
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L, Snoeys J, Jacobs F, Li LY, Poggesi I, Verboven P, Goris I, Scheers E, Wynant I, Monshouwer M, Mamidi RNVS. De Zwart L, et al. Among authors: wynant i. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1107-1118. doi: 10.1002/psp4.12682. Epub 2021 Aug 11. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34273250 Free PMC article.
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
De Jonghe S, Proctor J, Vinken P, Feyen B, Wynant I, Marien D, Geys H, Mamidi RN, Johnson MD. De Jonghe S, et al. Among authors: wynant i. Chem Biol Interact. 2014 Dec 5;224:1-12. doi: 10.1016/j.cbi.2014.09.018. Epub 2014 Oct 5. Chem Biol Interact. 2014. PMID: 25289773